Cargando…
A human liver chimeric mouse model for non-alcoholic fatty liver disease
BACKGROUND & AIMS: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and a...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138774/ https://www.ncbi.nlm.nih.gov/pubmed/34036256 http://dx.doi.org/10.1016/j.jhepr.2021.100281 |
_version_ | 1783695874651586560 |
---|---|
author | Bissig-Choisat, Beatrice Alves-Bezerra, Michele Zorman, Barry Ochsner, Scott A. Barzi, Mercedes Legras, Xavier Yang, Diane Borowiak, Malgorzata Dean, Adam M. York, Robert B. Galvan, N. Thao N. Goss, John Lagor, William R. Moore, David D. Cohen, David E. McKenna, Neil J. Sumazin, Pavel Bissig, Karl-Dimiter |
author_facet | Bissig-Choisat, Beatrice Alves-Bezerra, Michele Zorman, Barry Ochsner, Scott A. Barzi, Mercedes Legras, Xavier Yang, Diane Borowiak, Malgorzata Dean, Adam M. York, Robert B. Galvan, N. Thao N. Goss, John Lagor, William R. Moore, David D. Cohen, David E. McKenna, Neil J. Sumazin, Pavel Bissig, Karl-Dimiter |
author_sort | Bissig-Choisat, Beatrice |
collection | PubMed |
description | BACKGROUND & AIMS: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and animal studies, our understanding of NAFLD pathogenesis remains limited. To better study the molecular changes driving the condition we aimed to generate a humanised NAFLD mouse model. METHODS: We generated TIRF (transgene-free Il2rg(-/-)/Rag2(-/-)/Fah(-/-)) mice, populated their livers with human hepatocytes, and fed them a Western-type diet for 12 weeks. RESULTS: Within the same chimeric liver, human hepatocytes developed pronounced steatosis whereas murine hepatocytes remained normal. Unbiased metabolomics and lipidomics revealed signatures of clinical NAFLD. Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes, demonstrating stark species differences in liver function. Regulatory network analysis indicated close agreement between our model and clinical NAFLD with respect to transcriptional control of cholesterol biosynthesis. CONCLUSIONS: These NAFLD xenograft mice reveal an unexpected degree of evolutionary divergence in food metabolism and offer a physiologically relevant, experimentally tractable model for studying the pathogenic changes invoked by steatosis. LAY SUMMARY: Fatty liver disease is an emerging health problem, and as there are no good experimental animal models, our understanding of the condition is poor. We here describe a novel humanised mouse system and compare it with clinical data. The results reveal that the human cells in the mouse liver develop fatty liver disease upon a Western-style fatty diet, whereas the mouse cells appear normal. The molecular signature (expression profiles) of the human cells are distinct from the mouse cells and metabolic analysis of the humanised livers mimic the ones observed in humans with fatty liver. This novel humanised mouse system can be used to study human fatty liver disease. |
format | Online Article Text |
id | pubmed-8138774 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-81387742021-05-24 A human liver chimeric mouse model for non-alcoholic fatty liver disease Bissig-Choisat, Beatrice Alves-Bezerra, Michele Zorman, Barry Ochsner, Scott A. Barzi, Mercedes Legras, Xavier Yang, Diane Borowiak, Malgorzata Dean, Adam M. York, Robert B. Galvan, N. Thao N. Goss, John Lagor, William R. Moore, David D. Cohen, David E. McKenna, Neil J. Sumazin, Pavel Bissig, Karl-Dimiter JHEP Rep Research Article BACKGROUND & AIMS: The accumulation of neutral lipids within hepatocytes underlies non-alcoholic fatty liver disease (NAFLD), which affects a quarter of the world’s population and is associated with hepatitis, cirrhosis, and hepatocellular carcinoma. Despite insights gained from both human and animal studies, our understanding of NAFLD pathogenesis remains limited. To better study the molecular changes driving the condition we aimed to generate a humanised NAFLD mouse model. METHODS: We generated TIRF (transgene-free Il2rg(-/-)/Rag2(-/-)/Fah(-/-)) mice, populated their livers with human hepatocytes, and fed them a Western-type diet for 12 weeks. RESULTS: Within the same chimeric liver, human hepatocytes developed pronounced steatosis whereas murine hepatocytes remained normal. Unbiased metabolomics and lipidomics revealed signatures of clinical NAFLD. Transcriptomic analyses showed that molecular responses diverged sharply between murine and human hepatocytes, demonstrating stark species differences in liver function. Regulatory network analysis indicated close agreement between our model and clinical NAFLD with respect to transcriptional control of cholesterol biosynthesis. CONCLUSIONS: These NAFLD xenograft mice reveal an unexpected degree of evolutionary divergence in food metabolism and offer a physiologically relevant, experimentally tractable model for studying the pathogenic changes invoked by steatosis. LAY SUMMARY: Fatty liver disease is an emerging health problem, and as there are no good experimental animal models, our understanding of the condition is poor. We here describe a novel humanised mouse system and compare it with clinical data. The results reveal that the human cells in the mouse liver develop fatty liver disease upon a Western-style fatty diet, whereas the mouse cells appear normal. The molecular signature (expression profiles) of the human cells are distinct from the mouse cells and metabolic analysis of the humanised livers mimic the ones observed in humans with fatty liver. This novel humanised mouse system can be used to study human fatty liver disease. Elsevier 2021-03-21 /pmc/articles/PMC8138774/ /pubmed/34036256 http://dx.doi.org/10.1016/j.jhepr.2021.100281 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Article Bissig-Choisat, Beatrice Alves-Bezerra, Michele Zorman, Barry Ochsner, Scott A. Barzi, Mercedes Legras, Xavier Yang, Diane Borowiak, Malgorzata Dean, Adam M. York, Robert B. Galvan, N. Thao N. Goss, John Lagor, William R. Moore, David D. Cohen, David E. McKenna, Neil J. Sumazin, Pavel Bissig, Karl-Dimiter A human liver chimeric mouse model for non-alcoholic fatty liver disease |
title | A human liver chimeric mouse model for non-alcoholic fatty liver disease |
title_full | A human liver chimeric mouse model for non-alcoholic fatty liver disease |
title_fullStr | A human liver chimeric mouse model for non-alcoholic fatty liver disease |
title_full_unstemmed | A human liver chimeric mouse model for non-alcoholic fatty liver disease |
title_short | A human liver chimeric mouse model for non-alcoholic fatty liver disease |
title_sort | human liver chimeric mouse model for non-alcoholic fatty liver disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138774/ https://www.ncbi.nlm.nih.gov/pubmed/34036256 http://dx.doi.org/10.1016/j.jhepr.2021.100281 |
work_keys_str_mv | AT bissigchoisatbeatrice ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT alvesbezerramichele ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT zormanbarry ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT ochsnerscotta ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT barzimercedes ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT legrasxavier ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT yangdiane ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT borowiakmalgorzata ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT deanadamm ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT yorkrobertb ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT galvannthaon ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT gossjohn ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT lagorwilliamr ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT mooredavidd ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT cohendavide ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT mckennaneilj ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT sumazinpavel ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT bissigkarldimiter ahumanliverchimericmousemodelfornonalcoholicfattyliverdisease AT bissigchoisatbeatrice humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT alvesbezerramichele humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT zormanbarry humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT ochsnerscotta humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT barzimercedes humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT legrasxavier humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT yangdiane humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT borowiakmalgorzata humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT deanadamm humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT yorkrobertb humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT galvannthaon humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT gossjohn humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT lagorwilliamr humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT mooredavidd humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT cohendavide humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT mckennaneilj humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT sumazinpavel humanliverchimericmousemodelfornonalcoholicfattyliverdisease AT bissigkarldimiter humanliverchimericmousemodelfornonalcoholicfattyliverdisease |